Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

Table 2 Comparison of anthropometric analysis between baseline and 6 months, and comparison of absolute change from baseline between the two groups

Variable	Non-EPA group (n = 53)		EPA group (n = 54)		P value
Variable	Baseline	6-month	Baseline	6-month	P value
Weight (kg)	67.8 ± 10.0	66.3 ± 9.9*	67.6 ± 11.2	66.4 ± 11.0*	0.97
Absolute Δ	−1.1 (−3.0, 0.0)		−1.0 (−2.8, 0.0)		0.49
Body mass index (kg/m²)	25.4 ± 2.4	24.8 ± 2.4*	25.3 ± 2.9	24.8 ± 2.8*	0.90
Absolute Δ	−0.5 (−1.1, 0.0)		−0.4 (−1.0, 0.0)		0.53
Systolic blood pressure (mmHg)	135.6 ± 15.0	133.0 ± 17.1	132.9 ± 19.5	129.7 ± 19.0	0.35
Absolute Δ	−3.0 (−13.0, 8.0)		−3.0 (−10.0, 4.0)		0.89
Diastolic blood pressure (mmHg)	78.6 ± 9.8	77.5 ± 10.9	77.2 ± 11.7	76.3 ± 8.2	0.51
Absolute Δ	−2.0 (−7.0, 3.3)		0.0 (−7.0, 6.0)		0.63

P values represent comparison of each values between groups at 6 months except for absolute Δ
As for absolute Δ of each values, P values represent comparison between the two groups
Values are presented as mean ± standard deviation or medians and interquartile ranges, as indicated
* P < 0.001 vs baseline

ISSN: 1475-2840